BACKGROUND: Data comparing abacavir/lamivudine versus tenofovir/emtricitabine in antiretroviral-naive patients are controversial. We compared 48-week efficacy and safety of these combinations as substitutes of nucleosides in patients with virological suppression. METHODS: We randomly assigned 333 HIV-1-infected patients onlamivudine-containing triple regimens with <200 copies per milliliter for at least 6 months to switch their nucleosides to either abacavir/lamivudine (n = 167) or tenofovir/emtricitabine (n = 166). The primary outcome was treatment failure ["switching = failure" intention to treat (ITT) analysis, noninferiority margin 12.5%]. Secondary outcomes were time to treatment failure, virological failure, adverse events, and changes in CD4 count, fasting plasma lipids, lipodystrophy, body fat, bone mineral density, and renal function. RESULTS:Treatment failure occurred in 32 patients (19%) on abacavir/lamivudine and 22 patients (13%) on tenofovir/emtricitabine [difference 5.9%; (95% confidence interval -2.1% to 14.0%), P = 0.06]. Four patients in the abacavir/lamivudine group versus none in the tenofovir/emtricitabine group developed virological failure [difference 2.4; (95% confidence interval 0.05 to 6.0), P = 0.04]. Twenty-three patients (14%) assigned to abacavir/lamivudine and 10 (6%) to tenofovir/lamivudine experienced grade 3 or 4 adverse effects (P = 0.03). CD4 counts and plasma lipids showed higher increments in the abacavir/lamivudine group than in the tenofovir/emtricitabine group. CONCLUSIONS: In HIV-1-infected patients with virological suppression, abacavir/lamivudine did not meet the noninferiority outcome for treatment efficacy compared with tenofovir/emtricitabine.
RCT Entities:
BACKGROUND: Data comparing abacavir/lamivudine versus tenofovir/emtricitabine in antiretroviral-naive patients are controversial. We compared 48-week efficacy and safety of these combinations as substitutes of nucleosides in patients with virological suppression. METHODS: We randomly assigned 333 HIV-1-infectedpatients on lamivudine-containing triple regimens with <200 copies per milliliter for at least 6 months to switch their nucleosides to either abacavir/lamivudine (n = 167) or tenofovir/emtricitabine (n = 166). The primary outcome was treatment failure ["switching = failure" intention to treat (ITT) analysis, noninferiority margin 12.5%]. Secondary outcomes were time to treatment failure, virological failure, adverse events, and changes in CD4 count, fasting plasma lipids, lipodystrophy, body fat, bone mineral density, and renal function. RESULTS: Treatment failure occurred in 32 patients (19%) on abacavir/lamivudine and 22 patients (13%) on tenofovir/emtricitabine [difference 5.9%; (95% confidence interval -2.1% to 14.0%), P = 0.06]. Four patients in the abacavir/lamivudine group versus none in the tenofovir/emtricitabine group developed virological failure [difference 2.4; (95% confidence interval 0.05 to 6.0), P = 0.04]. Twenty-three patients (14%) assigned to abacavir/lamivudine and 10 (6%) to tenofovir/lamivudine experienced grade 3 or 4 adverse effects (P = 0.03). CD4 counts and plasma lipids showed higher increments in the abacavir/lamivudine group than in the tenofovir/emtricitabine group. CONCLUSIONS: In HIV-1-infectedpatients with virological suppression, abacavir/lamivudine did not meet the noninferiority outcome for treatment efficacy compared with tenofovir/emtricitabine.
Authors: Rebecca Scherzer; Michelle Estrella; Yongmei Li; Andy I Choi; Steven G Deeks; Carl Grunfeld; Michael G Shlipak Journal: AIDS Date: 2012-04-24 Impact factor: 4.177
Authors: Kathleen Mulligan; David V Glidden; Peter L Anderson; Albert Liu; Vanessa McMahan; Pedro Gonzales; Maria Esther Ramirez-Cardich; Sirianong Namwongprom; Piotr Chodacki; Laura Maria Carvalo de Mendonca; Furong Wang; Javier R Lama; Suwat Chariyalertsak; Juan Vicente Guanira; Susan Buchbinder; Linda-Gail Bekker; Mauro Schechter; Valdilea G Veloso; Robert M Grant Journal: Clin Infect Dis Date: 2015-04-23 Impact factor: 9.079
Authors: R Palacios; I A Pérez-Hernández; M A Martínez; M L Mayorga; C M González-Domenech; M Omar; J Olalla; A Romero; J M Romero; I Pérez-Camacho; J Hernández-Quero; J Santos Journal: Eur J Clin Microbiol Infect Dis Date: 2016-02-15 Impact factor: 3.267
Authors: Heidi M Crane; Carl Grunfeld; James H Willig; Michael J Mugavero; Stephen Van Rompaey; Richard Moore; Benigno Rodriguez; Betsy J Feldman; Michael M Lederman; Michael S Saag; Mari M Kitahata Journal: AIDS Date: 2011-01-14 Impact factor: 4.177
Authors: Esteban Martínez; Polyana M d'Albuquerque; Ignacio Pérez; Judit Pich; José M Gatell Journal: AIDS Res Hum Retroviruses Date: 2012-09-24 Impact factor: 2.205